

# Aerocrine

Press release  
7 February, 2008

## **Aerocrine appoints new President of Aerocrine Inc.**

**SOLNA, Sweden – 7 February, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the appointment of Chip Neff to the position of President of Aerocrine’s US subsidiary Aerocrine Inc., effective from 25 February 2008. Chip Neff will succeed Trevor Bourke, who has led the development of Aerocrine Inc since 2002. Trevor Bourke will remain at Aerocrine Inc during the transition, prior to taking up a new role in Europe.**

Chip Neff joins Aerocrine from HemoCue/Quest Diagnostics where he has been responsible for sales growth and marketing in North America for the last ten years. Chip has more than twenty years experience in sales and marketing management within the US medtech industry where he has previously successfully worked for Mallinckrodt Medical, Nova Biomedical and Marion Laboratories.

“Aerocrine is entering into a new phase in North America with the introduction of a revolutionary new product to new customer groups. This will require continued strong leadership, as well as solid experience from operative sales and marketing of new healthcare products and methods”, says Paul de Potocki, CEO of Aerocrine AB. “Chip’s exceptional results within domestic US sales, and his extensive experience of developing successful commercial organisations, will be of great value in maintaining Aerocrine’s market leadership in the US.”

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

Anna Malm Bernsten, Vice President Global Sales, telephone: +46 8 505 77 962

### **About Aerocrine**

Aerocrine AB (publ) is a medical technology concern focused on the improved management and care of patients with airway inflammation. The company markets NIOX® Flex globally, and also markets NIOX MINO® – which represents a new generation of hand-held products – in Europe. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of asthma patients. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June, 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at noon on January the 7 <sup>th</sup> 2008.
--